OncoQR announces the preclinical dose-ranging findings for TYG100. A single dose achieved clinical levels of antibodies in NHP including patients treated concurrently with gemcitabine.
OncoQR and TYG oncology Ltd announce the expansion of their collaboration agreement to tackle additional cancers.
